CompletedPhase 3

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

Effect of Genetic Variation in the GLP-1 Receptor on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetic Humans

Lead sponsor

Adrian Vella

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04466566

Org study ID20-003984

Secondary IDR01DK126206

Timeline

Milestones

Study first posted2020-07-10actual

Study start2022-10-17actual

Primary completion2025-09-30actual

Study completion2025-12-30actual

Last update posted2026-01-22actual

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age25 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•40 nondiabetic subjects will be recruited.

•20 subjects with the AA genotype at rs3765467 and remainder will have the GG genotype.

•Individuals encompassing the age span of 25-65 years.

Exclusion criteria

•Individuals under 25 and over 65 years of age.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.